Pre-made Telazorlimab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Telazorlimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Telazorlimab (previously ISB 830 or GBR 830) is an OX40 antagonist monoclonal antibody, being developed by Ichnos Sciences (a spin-off of Glenmark.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-558-1mg	1mg	3090
GMP-Bios-ab-558-10mg	10mg	Inquiry
GMP-Bios-ab-558-100mg	100mg	Inquiry
GMP-Bios-ab-558-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Telazorlimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
INN Name	Telazorlimab
Target	CD134
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Glenmark Pharmaceuticals
Conditions Approved	na
Conditions Active	Atopic dermatitis;Systemic lupus erythematosus;Ulcerative colitis;Rheumatoid arthritis
Conditions Discontinued	na
Development Tech	na